Freeline Therapeutics Holdings plc (FRLN) Financials

FRLN Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 49.2 million 19.2 million
June 30, 2023 62.7 million 20.6 million
March 31, 2023 86.6 million 34.2 million
Dec. 31, 2022 86.6 million 34.2 million

FRLN Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -8.7 million 895000
June 30, 2023 -17.5 million 1.1 million
March 31, 2023 -23.7 million 1.0 million
Dec. 31, 2022 -23.7 million 1.0 million

FRLN Net Income

No data available :(

FRLN Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 29.5 million - 4.0 million
June 30, 2023 38.8 million - 4.8 million
March 31, 2023 47.3 million - 5.4 million
Dec. 31, 2022 47.3 million - 5.9 million

FRLN Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 4.4 million
June 30, 2023 4.3 million
March 31, 2023 4.3 million
Dec. 31, 2022 59.3 billion

FRLN Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 6000 5.8 million 6.4 million -
June 30, 2023 256000 8.8 million 9.5 million -
March 31, 2023 3.9 million 12.6 million 5.6 million -
Dec. 31, 2022 3.9 million 12.6 million 5.6 million -

FRLN Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 5000 383759
June 30, 2023 617000 434392
March 31, 2023 - 317360
Dec. 31, 2022 - -

FRLN

Price: $6.49

52 week price:
2.11
9.17

Earnings Per Share: -11.45 USD

P/E Ratio: -0.56

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 189900

Market Capitalization: 28.2 million

Links: